Method: Prospective descriptive study on 28 eyes of 27 patients with exudative age-related macular degeneration who were indicated for intraocular injection of Bevacizumab after 1 month, 2 months and 3 months from 10/2021 to 8/2022 at the Department of Ophthalmology - National Geriatric Hospital.